Group 1 - The company did not distribute cash dividends, issue bonus shares, or increase capital from reserves during the reporting period [3] - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period [5] - There were no preferred shareholders or related holdings reported during the reporting period [5] Group 2 - All directors attended the board meeting to review the report [2] - The report does not require retrospective adjustments or restatements of previous accounting data [4] - There are no significant matters reported during the period [5]

（文章来源：每日经济新闻） 丰原药业（SZ 000153，收盘价：7.14元）8月21日晚间发布半年度业绩报告称，2025年上半年营业收入 约20.27亿元，同比减少12.16%；归属于上市公司股东的净利润约7628万元，同比减少23.88%；基本每 股收益0.1641元，同比减少23.89%。 ...

Core Insights - Fengyuan Pharmaceutical (000153.SZ) reported a revenue of 2.027 billion yuan for the first half of 2025, representing a year-on-year decline of 12.16% [1] - The net profit attributable to shareholders was 76.2785 million yuan, down 23.88% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 60.5262 million yuan, a decrease of 29.32% compared to the previous year [1] - The basic earnings per share stood at 0.1641 yuan [1]

安徽丰原药业股份有限公司 2025 年半年度财务报告 安徽丰原药业股份有限公司 2025 年半年度财务报告 2025 年 8 月 1 安徽丰原药业股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：安徽丰原药业股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 188,225,673.83 | 250,820,984.69 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | | | | 应收账款 | 1,085,026,202.64 | 934,569,467.81 | | 应收款项融资 | 25,041,019.15 | 32,676,575.46 | | 预付款项 | 64,861,353.22 | 83,581,427.14 | | 应收保费 | | ...

安徽丰原药业股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：人民币万元 非经营性资金占用 资金占用方名称 占用方与上市公 司的关联关系 上市公司核算的 会计科目 2025 年期初占用 资金余额 2025 年半年度占用累计 发生金额（不含利息） 2025 年半年度占用 资金的利息（如有） 2025 年半年度偿 还累计发生金额 2025 年半年度期 末占用资金余额 占用形成原因 占用性质 控股股东、实际控制 人及其附属企业 非经营性占用 小计 前控股股东、实际控 制人及其附属企业 非经营性占用 小计 其他关联方及其附 属企业 非经营性占用 小计 总计 其他关联资金往来 资金往来方名称 往来方与上市公 司的关联关系 上市公司核算的 会计科目 2025 年期初往来 资金余额 2025 年半年度往来累计 发生金额（不含利息） 2025 年半年度往来 资金的利息（如有） 2025 年半年度偿 还累计发生金额 2025 年半年度期 末往来资金余额 往来形成原因 往来性质（经营性往 来、非经营性往来） 控股股东、实际控制 人及其附属企业 上市公司的子公司 及其附属企业 安徽泰服医药有限公司 ...

安徽丰原药业股份有限公司 2025 年半年度报告全文 安徽丰原药业股份有限公司 2025 年半年度报告 2025 年 8 月 1 安徽丰原药业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准 确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 公司负责人汝添乐、主管会计工作负责人李俊及会计机构负责人(会计主管人员)陈 志锐声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告涉及公司经营计划等前瞻性陈述，不构成公司对投资者的实质性承诺， 敬请广大投资者注意投资风险。 新药研发投资大、周期长、环节多，风险高。根据《药品注册管理办法》等法规的 相关规定，新药注册一般需经过临床前研究、临床实验、新药申报与审批等阶段，容易 受到一些不可预测因素的影响，如果最终未能通过新药注册审批，可直接影响到公司前 期投入的回收和预期效益的实现。 | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- | --- | | 第二节 | ...

Core Viewpoint - Fengyuan Pharmaceutical's stock price has increased by 0.99% to 7.14 yuan, with a total market capitalization of 3.318 billion yuan and a price-to-earnings ratio of 21.82 times [1] Group 1: Financial Performance - The company reported that its revenue contributions from drug manufacturing and retail distribution are 46.65% and 49.75% respectively for the year 2024 [1] - The total trading volume for the day was 117 million yuan, with the stock reaching a high of 7.16 yuan and a low of 7.02 yuan during trading [1] Group 2: Share Transfer Announcement - On August 11, the company announced that its controlling shareholder, Fengyuan Group, along with its concerted parties, plans to transfer 23.6986 million shares, representing 5.1% of the total share capital, to Hainan Guihe Dayi Investment Partnership through a private agreement [1] - The transfer price is set at 6.72 yuan per share, totaling 159 million yuan, with the acquiring party expressing confidence in the company's future development [1]

Core Viewpoint - Fengyuan Pharmaceutical (000153) announced the transfer of 23.6986 million shares, representing 5.1% of the total share capital, from its controlling shareholder Anhui Fengyuan Group Co., Ltd. to Hainan Guihe Dayi Investment Partnership (Limited Partnership) at a price of 6.72 yuan per share, totaling 159 million yuan, indicating recognition of the company's future development prospects and investment value by Guihe Dayi [1] Group 1 - The controlling shareholder and its concerted party plan to transfer shares through an agreement [1] - The total number of shares being transferred is 23.6986 million, which constitutes 5.1% of the company's total share capital [1] - The agreed transfer price is 6.72 yuan per share, leading to a total transaction value of 159 million yuan [1]

格隆汇8月11日丨丰原药业(000153.SZ)公布，公司控股股东安徽丰原集团有限公司(简称"丰原集团")及 其一致行动人马鞍山丰原企业管理有限公司(简称"马鞍山丰原")拟通过协议转让方式，向海南贵和达毅 投资合伙企业(有限合伙)(简称"贵和达毅")转让其持有的公司股份合计23,698,554股，占公司总股本的 5.10%。转让价格为6.72元/股，股份转让总价款合计为人民币1.59亿元。 ...

Core Viewpoint - Fengyuan Pharmaceutical (000153) announced on August 11 that its controlling shareholder, Fengyuan Group, along with its concerted party, Ma'anshan Fengyuan Enterprise Management Co., Ltd., signed a share transfer agreement with Hainan Guihe Dayi Investment Partnership (Limited Partnership) to transfer a total of 5.1% of the company's shares at a price of 6.72 yuan per share, amounting to a total consideration of 159 million yuan [1]. Group 1 - The share transfer involves a total of 5.1% of Fengyuan Pharmaceutical's shares [1]. - The agreed transfer price is 6.72 yuan per share [1]. - The total transaction value is 159 million yuan [1].